Data on the benefit of percutaneous left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) who experience stroke despite chronic oral anticoagulation (OAC) are limited and not always consistent.
To evaluate the association between LAAO and recurrent stroke or mortality using a pre...
L. Giovachini, J. Mesnier, T. Pommier et al.· European Heart Journal· 0 citations
Left atrial appendage occlusion (LAAO) is increasingly performed in patients with atrial fibrillation at high thromboembolic risk and contraindicated to long-term oral anticoagulation due to major bleeding risk. However, the incidence, determinants, and prognostic impact of in-hospital complications remain incomp...
T. Pommier, C. Lamarre, L. Giovachini et al.· European Heart Journal· 0 citations
In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.
J. Silvain, Ki H. Choi, Victorien Monguillon et al.· The Lancet· 1 citation
In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.
G. Montalescot, E. Ferrari, G. Souteyrand et al.· Journal of the American Medi...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.